source
- Amgen submits new analysis to FDA to defend continued availability of TavneosAmgen has provided the FDA with a fresh analysis concerning its rare-disease therapy Tavneos, aiming to address the agency’s concerns. The company says the independent reevaluation supports the dr…
- Merck grants royalty-free licenses for experimental HIV prevention pill to generic makers in 129 low-income countriesMerck announced voluntary licensing agreements that let generic manufacturers produce its experimental HIV prevention pill, known as alimatravir, in low- and middle-income markets. The deals cover…